Is the regulation by miRNAs of NTPDase1 and ecto-5’-nucleotidase genes involved with the different profiles of breast cancer subtypes?

Silva, Fernanda Cardoso da; Neto, Angelo Borges de Melo; Martins, Christina Aparecida; Cardoso, Thaís Cunha de Sousa; Gomes, Matheus de Souza; Araújo, Thaise Gonçalves; Fürstenau, Cristina Ribas

doi:10.1007/s11302-021-09824-4

Cited by 5 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, miR-101 is recognized as a suppressor that hinders the migration, metastasis, and growth of BC. In TNBC, the lower expression of miR-101 is linked to an increased aggressiveness, and administering miRNA has been shown to impede cell proliferation and migration [ 12 ]. Similarly, miR-340 is reported to be a breast cancer suppressor due to its capacity to inhibit tumor cells migration and tissue invasion.…”

Section: Resultsmentioning

confidence: 99%

“…Similarly, miR-340 is reported to be a breast cancer suppressor due to its capacity to inhibit tumor cells migration and tissue invasion. Moreover, overexpressing miR-340 in TNBC cell lines led to a significant reduction in the proliferation and migration of these cells [ 12 ].…”

Section: Resultsmentioning

confidence: 99%

“…However, despite the numerous studies contributing to characterizing subtypes within TNBC, the underlying factors driving this cancer remain elusive [ 11 ]. Therefore, substantial research is now ongoing to better understand the molecular changes responsible for the development and progression of TNBC, with the ultimate goal of identifying novel molecular biomarkers which can be effectively targeted by therapies and which could improve the prognosis of this aggressive tumor [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

Pastena,

Perera,

Martinino

et al. 2024

IJMS

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, marked by poor outcomes and dismal prognosis. Due to the absence of targetable receptors, chemotherapy still represents the main therapeutic option. Therefore, current research is now focusing on understanding the specific molecular pathways implicated in TNBC, in order to identify novel biomarker signatures and develop targeted therapies able to improve its clinical management. With the aim of identifying novel molecular features characterizing TNBC, elucidating the mechanisms by which these molecular biomarkers are implicated in the tumor development and progression, and assessing the impact on cancerous cells following their inhibition or modulation, we conducted a literature search from the earliest works to December 2023 on PubMed, Scopus, and Web Of Science. A total of 146 studies were selected. The results obtained demonstrated that TNBC is characterized by a heterogeneous molecular profile. Several biomarkers have proven not only to be characteristic of TNBC but also to serve as potential effective therapeutic targets, holding the promise of a new era of personalized treatments able to improve its prognosis. The pre-clinical findings that have emerged from our systematic review set the stage for further investigation in forthcoming clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

Pastena,

Perera,

Martinino

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…And a search for target genes of miR-193b led to the identification of 6 different factors, including CD73, but effects of miR-193b overexpression on CD73 expression on mRNA and protein level were not analyzed [ 25 ]. In breast cancer, several breast cell lines were utilized to determine the gene expression of CD39 and CD73, and it was confirmed in silico analyses that the miRNAs miR-101-3p, miR-141-3p, and miR-340-5p were highly expressed in MCF7 cells and targeted CD73 [ 26 ].…”

Section: Purinergic Signalling Modulated By Mirnas In Cancersmentioning

confidence: 99%

MicroRNA: Crucial modulator in purinergic signalling involved diseases

Guo

Yang

et al. 2022

Purinergic Signalling

View full text Add to dashboard Cite

Both microRNAs (miRNAs) and purinergic signalling are widely and respectively expressed in various tissues of different organisms and play vital roles in a variety of physiological and pathological processes. Here, we reviewed the current publications contributed to the relationship of miRNAs and purinergic signalling in cardiovascular diseases, gastrointestinal diseases, neurological diseases, and ophthalmic diseases. We tried to decode the miRNAs-purinergic signalling network of purinergic signalling involved diseases. The evidence indicated that more than 30 miRNAs (miR-22, miR-30, miR-146, miR-150, miR-155, miR-187, etc.) directly or indirectly modulate P1 receptors (A1, A2A, A2B, A3), P2 receptors (P2X1, P2X3, P2X4, P2X7, P2Y2, P2Y6, P2Y12), and ecto-enzymes (CD39, CD73, ADA2); P2X7 and CD73 could be modulated by multiple miRNAs (P2X7: miR-21, miR-22, miR-30, miR-135a, miR-150, miR-186, miR-187, miR-216b; CD73: miR-141, miR-101, miR-193b, miR-340, miR-187, miR-30, miR-422a); miR-187 would be the common miRNA to modulate P2X7 and CD73.

show abstract

Comparative characterisation of an ecto‐5′‐nucleotidase (CD73) in non‐tumoral MCF10‐A breast cells and triple‐negative MDA‐MB‐231 breast cancer cells

Rocha‐Vieira,

Lacerda‐Abreu,

Carvalho‐Kelly

et al. 2024

Cell Biology International

View full text Add to dashboard Cite

Ecto‐5′‐nucleotidase (CD73) hydrolyses 5′AMP to adenosine and inorganic phosphate. Breast cancer cells (MDA‐MB‐231) express high CD73 levels, and this enzyme has been found to play a tumour‐promoting role in breast cancer. However, no studies have sought to investigate whether CD73 has differential affinity or substrate preferences between noncancerous and cancerous breast cells. In the present study, we aimed to biochemically characterise ecto‐5′‐nucleotidase in breast cancer cell lines and assess whether its catalytic function and tumour progression are correlated in breast cancer cells. The results showed that compared to nontumoral breast MCF‐10A cells, triple‐negative breast cancer MDA‐MB‐231 cells had a higher ecto‐5′‐nucleotidase expression level and enzymatic activity. Although ecto‐5′‐nucleotidase activity in the MDA‐MB‐231 cell line showed no selectivity among monophosphorylated substrates, 5′AMP was preferred by the MCF‐10A cell line. Compared to the MCF‐10A cell line, the MDA‐MB‐231 cell line has better hydrolytic ability, lower substrate affinity, and high inhibitory potential after treatment with a specific CD73 inhibitor α,β‑methylene ADP (APCP). Therefore, we demonstrated that a specific inhibitor of the ecto‐5‐nucleotidase significantly reduced the migratory and invasive capacity of MDA‐MB‐231 cells, suggesting that ecto‐5‐nucleotidase activity might play an important role in metastatic progression.

show abstract

Is the regulation by miRNAs of NTPDase1 and ecto-5’-nucleotidase genes involved with the different profiles of breast cancer subtypes?

Cited by 5 publications

References 63 publications

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

MicroRNA: Crucial modulator in purinergic signalling involved diseases

Comparative characterisation of an ecto‐5′‐nucleotidase (CD73) in non‐tumoral MCF10‐A breast cells and triple‐negative MDA‐MB‐231 breast cancer cells

Contact Info

Product

Resources

About